Clinical trials: Pancreas
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC)
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
- Trial name
- ALAFOSS-01 (NCT06599502)
- Testing
- AZD0022, Cetuximab
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Cancer
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
To assess the safety and efficacy of a combined therapy regimen of RX-0201 plus Gemcitabine, in subjects with metastatic pancreatic cancer.
- Trial name
- NCT01028495
- Testing
- RX-0201 plus Gemcitabine
- Where
- 10 sites in United States, India
- Volunteers
- 31 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of Personalized Neoantigen Cancer Vaccines
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03794128
- Testing
- Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- Gritstone bio, Inc.
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
- Trial name
- ORCHID-1 (NCT05716295)
- Testing
- MDK-703, Checkpoint Inhibitor, Immune
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Medikine, Inc.
Metastatic Pancreatic Adenocarcinoma
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
This study is a Phase 1b/2, dose-escalation, randomized, multicenter study to assess the efficacy, safety, tolerability, and PK of ivaltinostat in combination with capecitabine and capecitabine monotherapy in patients with…
- Trial name
- NCT05249101
- Testing
- Ivaltinostat, Capecitabine
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- CG Pharmaceuticals, Inc
Healthy, Cystic Fibrosis
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
The study is carried out to evaluate the safety, tolerability and pharmacokinetics of AeroVanc inhalation powder in healthy volunteers, and in patients with cystic fibrosis.
- Trial name
- NCT01537666
- Testing
- AeroVanc, IV vancomycin hydrochloride
- Where
- 2 sites in Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Savara Inc.
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CMG901.
- Conditions
- Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
- Trial name
- NCT04805307
- Testing
- CMG901
- Where
- 32 sites in China
- Volunteers
- 176 people
- Sponsor
- Keymed Biosciences Co.Ltd
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Cystic Fibrosis, Lung Infection Bacterial
Clinical Performance of the AtbFinder® Test System for Selection of Antibiotic Therapy in Persons With Cystic Fibrosis
This prospective case-control study was planned to evaluate the efficacy of antibiotic therapy selected with the AtbFinder® in persons with cystic fibrosis.
- Trial name
- NCT05584982
- Testing
- AtbFinder
- Volunteers
- 35 people
- Sponsor
- TGV-Dx
Exocrine Pancreatic Insufficiency
Phase III ALTU-135 CP Safety Trial
This is an open-label, single-arm clinical study investigating the long-term safety of ALTU-135 treatment in Chronic Pancreatitis (CP) patients with exocrine Pancreatic Insufficiency (PI).
- Trial name
- DIGEST CP (NCT00500084)
- Testing
- Liprotamase
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Anthera Pharmaceuticals
Chronic Pancreatitis, Pancreatectomy
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
This study assessed the effect of pancrelipase delayed release capsules on fat and nitrogen absorption in subjects with PEI due to Chronic Pancreatitis and Pancreatectomy.
- Conditions
- Chronic Pancreatitis, Pancreatectomy, Pancreatic Exocrine Insufficiency
- Trial name
- NCT00414908
- Testing
- Pancrelipase delayed release capsule
- Where
- 30 sites in United States, Bulgaria and 6 more
- Volunteers
- 52 people
- Sponsor
- Solvay Pharmaceuticals
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Cystic Fibrosis
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F).
- Trial name
- NCT03460990
- Testing
- VX-659/TEZ/IVA, TEZ/IVA, IVA
- Where
- 46 sites in United States, Australia and 4 more
- Volunteers
- 116 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cancer
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR.
- Trial name
- NCT05685524
- Testing
- DNA methylation test
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Wuhan Ammunition Life-tech Co., Ltd
Solid Tumors
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Participants with Select Advanced Solid Tumors
- Trial name
- NCT02503774
- Testing
- Oleclumab, Durvalumab
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 192 people
- Sponsor
- MedImmune LLC
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Pancreatic Cancer
32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer
This is the first study investigating the safety of 32P BioSilicon in patients with advanced,unresectable pancreatic cancer who are also receiving standard intravenous gemcitabine chemotherapy.
- Trial name
- NCT00346281
- Testing
- 32P BioSilicon
- Where
- 2 sites in Singapore, United Kingdom
- Volunteers
- 15 people
- Sponsor
- pSiMedica Limited
Biliary Tract Diseases
Spy II Clinical Registry
A prospective, multi-center registry for subjects undergoing Endoscopic retrograde Cholangiopancreatography (ERCP) and cholangioscopy for known or suspected pancreaticobiliary disease.
- Trial name
- NCT00751998
- Testing
- SpyGlass
- Where
- 15 sites in United States, Belgium and 4 more
- Volunteers
- 297 people
- Sponsor
- Boston Scientific Corporation